Pharmacological and clinical studies with Lomoparan, a low molecular weight glycosaminoglycan.
Nurmohamed
M T
MT
Centre for Hemostasis, Thrombosis and Atherosclerosis Research, Academic Medical Centre, Amsterdam, The Netherlands.
Fareed
J
J
Hoppensteadt
D
D
Walenga
J M
JM
ten Cate
J W
JW
D000818:Animals; D000925:Anticoagulants / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004353:Drug Evaluation, Preclinical; D005343:Fibrinolytic Agents / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006025:Glycosaminoglycans / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006497:Heparan Sulfate; D006801:Humans; D015994:Incidence; D008322:Mammals; D008970:Molecular Weight; D010974:Platelet Aggregation / Q000187:drug effects; D011183:Postoperative Complications / Q000517:prevention & control; D011817:Rabbits; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000139:chemically induced; D013924:Thrombophlebitis / Q000453:epidemiology / Q000517:prevention & control; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control
D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005343:Fibrinolytic Agents; D006025:Glycosaminoglycans; D006493:Heparin; D006497:Heparan Sulfate; C035838:danaparoid